期刊文献+

盐酸法舒地尔治疗急性缺血性脑血管病疗效观察 被引量:2

下载PDF
导出
摘要 目的评价Rho激酶抑制剂法舒地尔治疗急性缺血性脑卒中的疗效与安全性。方法急性缺血性脑卒中患者120例随机分为治疗组60例和对照组60例,2组均予以常规治疗,治疗组在此基础上给予盐酸法舒地尔静滴,对照组给予复方丹参注射液静滴。分别在入院时及治疗后2周对2组患者进行神经功能缺损评分并进行临床结局评定。结果治疗组神经功能缺损评分和临床结局改善情况均明显优于对照组。结论急性缺血性脑卒中发病后48 h内应用盐酸法舒地尔,可有效改善患者神经功能缺损情况和临床结局,无严重不良反应。
作者 孙沄
出处 《现代中西医结合杂志》 CAS 2011年第34期4371-4372,共2页 Modern Journal of Integrated Traditional Chinese and Western Medicine
  • 相关文献

参考文献7

  • 1Rikitake Y,Kim HH,Huang Z,et al. Inhibition of Rho kinase (R- OCK) leads to increased cerebral blood flow and stroke p rotection [J]. Stroke,2005,36(10):2251-2257.
  • 2各类脑血管疾病诊断要点[J].中华神经科杂志,1996,29(6):379-380. 被引量:33022
  • 3<脑卒中综合规范临床(内科)诊治研究方案>协作组.规范治疗急性脑卒中显著降低患者住院病死率[J].中华神经科杂志,2005,38(1):17-21. 被引量:74
  • 4脑卒中患者临床神经功能缺损程度评分标准(1995)[J].中华神经科杂志,1996,29(6):381-383. 被引量:15750
  • 5Shah DI,Singh M. Involvement of Rho-kinase in experimental vas- cular endothelial dysfunction [ J ]. Mol Cell Biochem, 2006,283 : 191 - 199.
  • 6Doe C, Bentley R, Behm DJ, et al. Novel rhokinase inhibitors with anti-inflammatory and vasodilatory activities [ J ]. J Pharmacol ExP Ther,2007,320 : 89 - 98.
  • 7Janeczek AH,Van-ahen PJ, Reyes HM,et al. Modulation of the cy- toskeleton and intracellular calcium in leukocyte exhibiting a cancer- associated chemotaxis defect[ J]. J Leukocyte Biol, 1993,54:351 - 359.

二级参考文献6

  • 1Roberts SE, Goldacre MJ. Case fatality rates after admission to hospital with stroke: linked database study. BMJ, 2003, 326:193-194.
  • 2Alberts MJ, Hademenos G, Latchaw RE, et al. Recommendations for the establishment of primary stroke centers. Brain Attack Coalition. JAMA, 2001, 283: 3102-3109.
  • 3Adams HP Jr, Bmtt TG, Furlan AJ, et al. Guidelines for the management of patients with acute ischemic stroke: a statement for healthcare professionals from a special writing group of the stroke council, American Heart Association. Circulation, 1994, 90 : 1558-1601.
  • 4Adams HP Jr, Adams RJ, Brott T, et al, Guidelines for the early management of patients with ischemic stroke, a scientific statement from the stroke council of the American Stroke Association. Stroke,2003, 34 : 1056-1083.
  • 5Stroke Unit Trialists Collaboration. Collaborative systematic review of the randomised trials of organised inpatients (stroke unit) care after stroke. BMJ, 1997, 314:1151-1159.
  • 6Evans A, Harraf F, Donaldson N, et al. Randomized controlled study of stroke unit care versus stroke team care indifferent stroke subtypes. Stroke, 2002,33:449-455.

共引文献42970

同被引文献14

  • 1余传庆,张梅,薛敏,宫琨.缺血性脑血管病患者脑动脉狭窄的分布特征及其危险因素分析[J].神经病学与神经康复学杂志,2010,7(3):142-145. 被引量:18
  • 2Gao Shan, Huang Jia-xing, Huang Yi-ning,et al. Atherosclerosis of the middle cerebral artery infarction narrow the pathogenesis [ J ]. Chinese Journal of Neurology, 2003,36 (2) : 155 - 157.
  • 3Kasner SE, Chimowitz MI, Lynn M J, et al. Predictors of stroke in the territory of a symptomatic intracranial arterial [ J ]. Circulation. 2006,113 (4) :555 - 563.
  • 4Chimowitz MI, Lynn M J, Howlett-Smith H, et al. Comparison of war- farin and aspirin for symptomatic intracranial arterial stenosis[ J]. N Engl J Med 2005,352(21 ) :1305 - 1316.
  • 5Jiang WJ,Yu W,Du B,et al. Outcome of patients with≥70% symp- tomatic intracranial stenosis after wingspan stenting [ J ]. Stroke. 2011,42(7) :1971 - 1975.
  • 6Hayreh SS. Ischaemic optic neuropathy. Prog Retin Eye Res 2009;28 ( i ) :34-62 3.
  • 7Seto M, Asanot T. Rho-Kinase inhibitors. Nihon Yakurigaku Zasshi 2011 ;138(3) :112-116 4.
  • 8Satoh S, Takayasu M, Kawasaki K, et al . Antivasospatic effects of hydroxyfasudil, a Rho-kinase inhibitor, after subarachnoid hemorrhage. J Pharmacol Sci 2012;118( 1 ) :92-98.
  • 9Siasios I, Kapsalaki EZ, Fountas KN, et al. Cerebral vasospasm pharmacological treatment: an update. Neurol Res lnt 2013; l0 (1):115-135.
  • 10李斗,王默力,李慎茂,凌锋.缺血性脑血管病患者脑动脉狭窄的分布特征及其危险因素分析[J].中华医学杂志,2008,88(17):1158-1162. 被引量:44

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部